GM27260
LCL from B-Lymphocyte
Description:
RETT SYNDROME, CONGENITAL VARIANT
FORKHEAD BOX G1; FOXG1
Repository
|
NIGMS Human Genetic Cell Repository
|
Subcollection |
Heritable Diseases PIGI Consented Sample FOXG1 |
Biopsy Source
|
Peripheral vein
|
Cell Type
|
B-Lymphocyte
|
Tissue Type
|
Blood
|
Transformant
|
Epstein-Barr Virus
|
Sample Source
|
LCL from B-Lymphocyte
|
Race
|
White
|
Ethnicity
|
Not Hispanic/Latino
|
Ethnicity
|
Italian, Eastern European
|
Country of Origin
|
BRAZIL
|
Family Member
|
1
|
Family History
|
N
|
Relation to Proband
|
proband
|
Confirmation
|
Molecular characterization before cell line submission to CCR
|
Species
|
Homo sapiens
|
Common Name
|
Human
|
Remarks
|
|
IDENTIFICATION OF SPECIES OF ORIGIN |
Species of Origin Confirmed by LINE assay |
|
Remarks |
Clinically affected; age at diagnosis 15 months; age of symptom onset 3 months; microcephaly; developmental delay; autistic symptoms; epilepsy; a submitted report summarized details of a translocation: t(2;14); the chr 14 breakpoint is located within the FOXG1 regulatory domain; this 14q12 breakpoint truncates the 3'UTR of the non-coding gene c14orf23 20-24 kb 3' to FOXG1 in a region associated with long-range position effect (LRPE) of FOXG1 with symptoms similar to those of point mutations within FOXG1; the chr 2 breakpoint is within 2q36.1, truncating the gene WDFY1 (expressed at low levels in tissue, not highly expressed in brain); EKG results were normal; EEG results were abnormal and showed signs of focal epilepsy; speech language therapy; physical therapy; occupational therapy; medications include keppra, clobazam, trihexyphenidyl, and melatonin; fibro is GM27261; mother is GM27262 (LCL) and father is GM27264 (LCL)/GM27265 (fibro). |
Split Ratio |
1:4 |
Temperature |
37 C |
Percent CO2 |
5% |
Percent O2 |
AMBIENT |
Medium |
Roswell Park Memorial Institute Medium 1640 with 2mM L-glutamine or equivalent |
Serum |
15% fetal bovine serum Not Inactivated |
Substrate |
None specified |
Subcultivation Method |
dilution - add fresh medium |
Supplement |
- |
|
|